InsidersTradesSigma
Follow the Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) stock price and the full insider trade history of the company, a listed equity based in Canada. Shares are quoted on CA CA, under the authority of SEDI. Market capitalisation: €28.5m. The latest transaction was filed on 2 June 2026 (16 - Acquisition or disposition under a prospectus exemption). Among the most active insiders: Mullally, William Hogan. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
Thiogenesis Therapeutics, Corp. is a biotechnology company focused on developing innovative treatments for serious diseases. Formerly known as Rozdil Capital Corporation, it is listed on the XTSE.